What question did this study set out to answer?

To synthesize structural, mechanistic, and clinical insights into the SF3b splicing complex and evaluate its potential as a therapeutic target in oncology.

August 16, 2026Blood AdvancesOpen Access

The SF3b complex in cancer: structural basis, molecular mechanisms, and therapeutic opportunities

View Full Paper

Ask AI

Bookmark

Authors

SLShuling LiChina-US (Henan) Hormel Cancer Institute LSLitong ShangHenan University of Engineering JYJiayi YangHenan University of Engineering

Discussion

Member takes

Overview

Mechanistic review uncovers SF3b complex structural dynamics and aberrant RNA splicing in hematologic malignancies, highlighting therapeutic strategies to target spliceosome function.

Key Points

To synthesize structural, mechanistic, and clinical insights into the SF3b splicing complex and evaluate its potential as a therapeutic target in oncology.
Synthesis of cryo-electron microscopy structural data characterizing SF3b conformational dynamics during spliceosome assembly and branch point sequence recognition.
Analysis of genetic perturbations, specifically recurrent SF3B1 mutations, and their downstream transcriptomic effects across myelodysplastic syndromes and chronic lymphocytic leukemia.
Evaluation of preclinical and early-phase clinical trial data assessing small-molecule SF3b inhibitors.
The SF3b complex undergoes dynamic transitions between open and closed conformations that stabilize pre-mRNA substrates throughout the splicing cycle.
Recurrent mutations in the core subunit SF3B1 alter branch point selection and generate aberrant transcript isoforms that reprogram oncogenic signaling pathways.
Pharmacological inhibition of SF3b demonstrates potent antitumor activity in preclinical models, though establishing a therapeutic window remains an ongoing clinical challenge.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a81799af2fb91fc834acca9 https://doi.org/10.1182/bloodadvances.2026020106

View Full Paper

Ask AI

Bookmark

August 16, 2026Blood AdvancesOpen Access

The SF3b complex in cancer: structural basis, molecular mechanisms, and therapeutic opportunities

View Full Paper

Ask AI

Bookmark

Authors

SLShuling LiChina-US (Henan) Hormel Cancer Institute LSLitong ShangHenan University of Engineering JYJiayi YangHenan University of Engineering

Discussion

Member takes

Overview

Mechanistic review uncovers SF3b complex structural dynamics and aberrant RNA splicing in hematologic malignancies, highlighting therapeutic strategies to target spliceosome function.

Key Points

To synthesize structural, mechanistic, and clinical insights into the SF3b splicing complex and evaluate its potential as a therapeutic target in oncology.
Synthesis of cryo-electron microscopy structural data characterizing SF3b conformational dynamics during spliceosome assembly and branch point sequence recognition.
Analysis of genetic perturbations, specifically recurrent SF3B1 mutations, and their downstream transcriptomic effects across myelodysplastic syndromes and chronic lymphocytic leukemia.
Evaluation of preclinical and early-phase clinical trial data assessing small-molecule SF3b inhibitors.
The SF3b complex undergoes dynamic transitions between open and closed conformations that stabilize pre-mRNA substrates throughout the splicing cycle.
Recurrent mutations in the core subunit SF3B1 alter branch point selection and generate aberrant transcript isoforms that reprogram oncogenic signaling pathways.
Pharmacological inhibition of SF3b demonstrates potent antitumor activity in preclinical models, though establishing a therapeutic window remains an ongoing clinical challenge.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a81799af2fb91fc834acca9 https://doi.org/10.1182/bloodadvances.2026020106

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark